Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Yu-Cheng Chang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
Metabolic Risk/Epidemiology
Article image
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
Diabetes Metab J. 2024;48(2):184-195.   Published online January 26, 2024
DOI: https://doi.org/10.4093/dmj.2023.0168
  • 26,173 View
  • 1,027 Download
  • 22 Web of Science
  • 25 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.

Citations

Citations to this article as recorded by  
  • Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model
    Magdy Fouad Tawfik, Yasmin Sayed Hussein, Amany Helmy Hasanin, Walaa Baher, Nashwa El-Khazragy, Farouk Guindi Moawad, Mawada Abou El-Khair, Salwa M. El-Sayed
    Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(4): 5559.     CrossRef
  • Endothelial CEPT1 Promotes Angiogenesis Through PPARα and VEGF-A Signaling
    Tariq J. Khan, Rodrigo Meade, Santiago Elizondo-Benedetto, Larisa Belaygorod, Omar Saffaf, Brigida Rusconi, Fong-Fu Hsu, Sangeeta Adak, Batool Arif, Mohamed S. Zaghloul, Tiandao Li, Bo Zhang, Clay F. Semenkovich, Mohamed A. Zayed
    Arteriosclerosis, Thrombosis, and Vascular Biology.2026; 46(1): 195.     CrossRef
  • The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications
    Song Wen, Chenglin Xu, Yue Yuan, Lijiao Chen, Yishu Ren, Zhimin Xu, Jianlan Jin, Jiyu Li, Ligang Zhou
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Fenofibrate vs. Omega-3 in Pediatric Hypertriglyceridemia: A Randomized Controlled Trial
    Setila Dalili, Shahin Koohmanaee, Afagh Hassanzadeh Rad, Parnian Nemati, Habibeh Mashayekhi-sardoo, Reza Bayat, Maryam Shahrokhi
    Journal of Pediatric Health Care.2026;[Epub]     CrossRef
  • Clinical efficacy of combining fenofibrate with statins in patients with diabetes and hyperlipidemia: a meta-analysis
    Jiayan Huang, Kaishun Meng, Huawei Qiu
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Naringenin modulate peroxisome proliferator-activated receptorα (PPARα) to ameliorate hepatic ferroptosis by restoring GPX4 during liver regeneration
    Haoran Zhong, Lei Sun, Jiajun Yu, Yanrong Wang, Tongjie Xu, Tingfeng Yang, Liangkun Liu, Jiayuan Chen, Jinwu Liu, Hao Chen, Wenguang Fu
    Biochemical Pharmacology.2026; 251: 118086.     CrossRef
  • Improved physicochemical and functional properties of soluble dietary Fiber from wheat bran by bacterial-enzymatic synergy
    Xiaoyu Guo, Jinghao Zhao, Peng Li, Kuijie Gong, Yuanda Song
    Food Chemistry.2026; 519: 149688.     CrossRef
  • Nicotine-associated cardiovascular dysfunction: From pharmacological insights to emerging therapeutic interventions
    Mohammad Atiqur Rahman, Md Areeful Haque, Saisudha Koka, Krishna M. Boini
    Biomedicine & Pharmacotherapy.2026; 200: 119610.     CrossRef
  • Beyond lipid-lowering effects: Challenges and insights in fenofibrate repurposing for oncology
    Liu Peng, Neng Zhu, Chan-Juan Zhang, Jun-Peng Long, Ya-Ning Shi, Qiong Yang, Yong-Zhen Gong, Li Qin
    Life Sciences.2026; 401: 124541.     CrossRef
  • Triterpenoids from ilicis rotundae cortex ameliorate hyperlipidemia by affecting bile acids-hepatointestinal FXR axis
    Wei Zeng, Mengjia Sun, Jiamin Cao, Caixin Chen, Shiqin Jiang, Yuanyuan Wang, Weiqun Yang, Zhongxiang Zhao, Jing Jin
    Phytomedicine.2025; 139: 156537.     CrossRef
  • Targeting of AMPK/MTOR signaling in the management of atherosclerosis: Outmost leveraging
    Hayder M. Al-kuraishy, Ghassan M. Sulaiman, Mayyadah H. Mohsin, Hamdoon A. Mohammed, Retaj A. Dawood, Ali K. Albuhadily, Ali I. Al-Gareeb, Salim Albukhaty, Mosleh M. Abomughaid
    International Journal of Biological Macromolecules.2025; 309: 142933.     CrossRef
  • Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet–induced steatotic liver disease
    Ming Jin, Rongmi Zhang, Wenwen Xin, Li Sun, Xue Fan, Qian Lu, Luyong Zhang, Zhenzhou Jiang, Qinwei Yu
    Molecular Pharmacology.2025; 107(7): 100047.     CrossRef
  • Fenofibrate ameliorates ocular surface inflammation in diabetic keratopathy
    Hassan Mansoor, Isabelle Xin Yu Lee, Chang Liu, Mingyi Yu, Charmaine Jan Li Toh, Victor Wei-Tsu Hsu, Fengyi Liu, Daqian Lu, Thomas Chuen Lam, Hong Chang Tan, Lei Zhou, Yu-Chi Liu
    The Ocular Surface.2025; 38: 31.     CrossRef
  • An exploration of molecular signaling in drug reprocessing for Oral Squamous Cell Carcinoma
    Ali Nakhaei, Sarah Marzoughi, Sahar Ghoflchi, Hossein Hosseini, Amir R. Afshari, Mohammad Jalili-Nik, Prashant Kesharwani, Amirhossein Sahebkar
    European Journal of Medicinal Chemistry.2025; 295: 117816.     CrossRef
  • Multi-Target Drug Strategies in the Treatment of Diabetic Retinopathy
    Angeline Julius, Suresh Malakondaiah, Ramalakshmi Subbarayalu, Remya Rajan Renuka, Raghu Babu Pothireddy
    SN Comprehensive Clinical Medicine.2025;[Epub]     CrossRef
  • Oxidative stress and inflammatory response in cerebral infarction due to hyperlipidemia and lipid-lowering, anti-inflammatory, and antioxidant therapy
    Xuan Zhou, You-Quan Gu, Lei Li
    Journal of the Neurological Sciences.2025; 476: 123620.     CrossRef
  • Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
    Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620.     CrossRef
  • Online bioactivity-guided HPLC-lipoprotein lipase system with medium-high pressure chromatography for rapid recognition and targeted isolation of natural affinity agents from Nitraria tangutorum
    Qianyu Wu, Yu Zhang, Ce Sun, Jun Dang
    Journal of Chromatography A.2025; 1762: 466384.     CrossRef
  • Combinatorial effects of Zingiber officinale and Citrus limon juices: Hypolipidemic and antioxidant insights from in vivo, in vitro, and in silico investigations
    Oussama Bekkouch, Ayoub Bekkouch, Hamza Elbouny, Ilham Touiss, Soufiane El Assri, Mohammed Choukri, Mohammed Bourhia, Kiryang Kim, Sojin Kang, Min Choi, Jinwon Choi, Hyo Jeong Kim, Chi-Hoon Ahn, Moon Nyeo Park, Bonglee Kim, Souliman Amrani, Muhammad Tariq
    PLOS One.2025; 20(9): e0319721.     CrossRef
  • Characterizing Fenofibrate-Related Renal and Urinary Adverse Events: A Comprehensive Analysis of FDA Adverse Event Reporting System Database
    Li Wang, Xiangyun Jin, YanChun Li
    Clinical Therapeutics.2025; 47(12): 1149.     CrossRef
  • THE EFFECT OF FENOFIBRATE ON THE DEVELOPMENT OF DIABETIC RETINOPATHY AND NEPHROPATHY – A REVIEW OF CURRENT RESEARCH
    Kacper Szeląg, Anna Opalińska, Cezary Lubas, Paula Folta, Joanna Kłosowska, Karolina Błądzińska, Maciej Błądziński, Małgorzata Zach, Piotr Świerczek, Antoni Kujawski
    International Journal of Innovative Technologies in Social Science.2025;[Epub]     CrossRef
  • Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT
    Eu Jeong Ku, Bongseong Kim, Kyungdo Han, Seung-Hwan Lee, Hyuk-Sang Kwon
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • The role of DGAT1 and DGAT2 in tumor progression via fatty acid metabolism: A comprehensive review
    Leisheng Wang, Shiwei Xu, Mengzhen Zhou, Hao Hu, Jinyou Li
    International Journal of Biological Macromolecules.2024; 278: 134835.     CrossRef
  • An exploratory investigation of lipid-lowering potential of spirulina ( Arthrospira platensis ) targeting apoprotein-E in chronic hyperlipidemic wistar albino rats
    Anum Nazir, Mahr Un Nisa, Mohamed H. Mahmoud, Ahmed M. El-Gazzar, Eliasse Zongo
    Cogent Food & Agriculture.2024;[Epub]     CrossRef
  • Advances in Understanding Diabetic Kidney Disease Progression and the Mechanisms of Acupuncture Intervention
    Jinyi Shan, Ziyi Cao, Siming Yu
    International Journal of General Medicine.2024; Volume 17: 5593.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP